Navigation Links
New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
Date:6/8/2008

, redness, pain, itching, hives, swelling, and inflammation.

Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment. Levemir(R) should not be diluted or mixed with any other insulin preparations or used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Prescribing information for Levemir(R) is available by contacting Novo Nordisk or visiting novonordisk-us.com.

Levemir(R) and FlexPen(R) are registered trademarks of Novo Nordisk A/S.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
2. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
3. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
4. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
5. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
6. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
7. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
8. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
9. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Final ... 25   The second edition of the ... excited to announce the final nominations for the 2014 ... on the evening of September 25 at The Taj Mahal Palace, ... applicants based on a variety of qualitative and quantitative ...
(Date:9/22/2014)... Sept. 22, 2014  Elusys Therapeutics, Inc. (Elusys), ... infectious disease, today announced it has completed three ... obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development ... from these studies support the safety and tolerability ... the intended therapeutic dose. The conclusion of these ...
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, ... therapeutic devices to address infectious disease, cancer and ... Advanced Research Projects Agency (DARPA) has informed the ... to proceed with year four of a five-year ... on September 30, 2011 under DARPA,s Dialysis-Like Therapeutics ...
Breaking Medicine Technology:Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
(Date:9/22/2014)... NJ. September 22, 2014. Kessler researchers have published ... 10-week psychoeducational wellness program in people with multiple ... overall mental health, perceived stress, and pain. ... for individuals living with MS: Description and outcomes" ... in the International Journal of MS Care ...
(Date:9/22/2014)... News) -- Two new prescription devices approved by the ... relief for people with migraine headaches who don,t tolerate ... One device -- the Cefaly -- is designed to ... -- is meant to be used when migraines first ... have been looking for alternative migraine treatments. Because these ...
(Date:9/22/2014)... Severe weather can occur with little warning, so ... part of National Preparedness Month, Amica Insurance is offering ... the unexpected:, , Build an emergency supply kit. ... one gallon of water per person per day for at least ... that includes pets so your family knows what to do and ...
(Date:9/22/2014)... New York / Westchester County, NY (PRWEB) September 22, ... Plastic Surgery (NYGPS) has joined the Department of Surgery ... The newly named Mount Sinai Doctors New York Group ... and the lower Hudson Valley access to a team ... plastic surgery techniques. Additionally, C. Andrew Salzberg, MD, ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... RIVERWOODS, Ill., June 10 As more and more employees ... a smaller and smaller percentage of them are actually signing ... the findings of the Spencer,s Benefits Reports 2009 ... COBRA in the 2008 plan year at companies covered by ...
... ARLINGTON, Va., June 10 The Generic Pharmaceutical Association ... and CEO Kathleen Jaeger regarding publication of the Federal ... , , "Today,s report from the FTC ... forward on passage of legislation that brings affordable biogenerics ...
... RIVERSIDE, California and NUREMBERG, Germany, June 10 ,Ziehm Imaging ... and Drug,Administration (FDA) has given 510k clearance for the ... RFD, for marketing and,sales within the United States. Designed ... the Ziehm Vision RFD,mobile C-arm combines the latest flat-panel ...
... Corporation (Nasdaq: KNSY ) is scheduled to present ... 18, 2009. , , Joseph W. Kaufmann, Kensey ... at approximately 9:00 a.m. (ET). To hear the live ... . The presentation materials will also be available on ...
... bacteria,s structure, , WEDNESDAY, June 10 (HealthDay News) -- ... a vacation. , Now, researchers have figured out how ... coli, or ETEC -- are able to make ... or "fimbriae" to attach, or bind, to the intestinal ...
... 2009, the Institute for Quality and Efficiency in Health ... assessment of certain newer antidepressants. The project commissioned by ... the benefit of three agents, reboxetine, mirtazapine and bupropion ... German drug approval status. Interested parties and institutions may ...
Cached Medicine News:Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 2Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 3Health News:Spencer's Benefits Reports COBRA Survey Finds Recession Takes Hold: More Were Eligible, Fewer Signed Up, Costs Stay High 4Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 2Health News:GPhA Statement on FTC Report on 'Follow-on Biologic Drug Competition' 3Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 2Health News:SVS 2009: Ziehm Imaging Sets a New Standard in Mobile Imaging With the Ziehm Vision RFD 3Health News:Finding May Lead to Vaccine for Traveler's Diarrhea 2Health News:Preliminary report on antidepressants published 2
... innovative stent allows the physician to intubate the ... with just topical anesthetic drops., ,The SRS is ... in three lengths 25mm, 30mm and 35mm (disposable ... stent is an anchor-shaped head to provide fixation. ...
... or somatomedin-C, is a peptide highly dependent ... promoting activity. IGF-I is transported in serum ... of growth disorders, measurements of IGF-I are ... hormone secretion. A normal plasma or serum ...
... is a high-throughput immunoassay system built around ... 2000 with the important addition of Logic ... to be designed for optimal performance with ... for critical assays such as the cardiac ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
Medicine Products: